A collaborative database and computational models for tuberculosis drug discovery.

Area of Science:

• Medicinal Chemistry
• Computational Biology
• Drug Discovery

Background:

• Mycobacterium tuberculosis (Mtb) infection remains a global health challenge, necessitating novel therapeutic strategies.
• Existing drug discovery efforts utilize high-throughput screening and computational methods to identify anti-Mtb compounds.

Purpose of the Study:

• To develop a comprehensive database (CDD TB) for Mtb research data.
• To identify key molecular descriptors and features that determine Mtb activity using cheminformatics.
• To build predictive models for prioritizing potential Mtb drug candidates.

Main Methods:

• Development of the CDD TB database for data integration and mining.
• Application of cheminformatics approaches to analyze Mtb active and inactive compound datasets.
• Generation and validation of Bayesian classification and computational pharmacophore models.
• Comparison of Mtb compound datasets with FDA-approved drugs.

Main Results:

• Polar surface area and pKa were identified as statistically significant determinants of Mtb activity.
• Bayesian models successfully discriminated active/inactive substructures within the CDD TB dataset.
• Computational pharmacophores effectively identified Mtb active compounds from datasets.

Conclusions:

• The integrated approach using a database, data analysis, and predictive modeling offers novel insights into Mtb drug discovery.
• Key 1D, 2D, and 3D molecular features can guide the prioritization of molecules with higher Mtb activity potential.
• This study provides a framework for mining chemical space to accelerate the development of new anti-tubercular agents.